Literature DB >> 22892985

Decrease in blood miR-296 predicts chemotherapy resistance and poor clinical outcome in patients receiving systemic chemotherapy for metastatic colon cancer.

N Shivapurkar, S Mikhail, R Navarro, W Bai, J Marshall, J Hwang, M Pishvaian, A Wellstein, A R He.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22892985      PMCID： PMC4344990          DOI： 10.1007/s00384-012-1560-1

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN： 0179-1958            Impact factor:   2.571


× No keyword cloud information.
  16 in total

1.  MicroRNA hsa-let-7e-5p as a potential prognosis marker for rectal carcinoma with liver metastases.

Authors:  Wenfeng Chen; Guosheng Lin; Yizhou Yao; Jishen Chen; Hanli Shui; Qinghai Yang; Xiaoya Wang; Xiaoyuan Weng; Ling Sun; Fei Chen; Sheng Yang; Yufeng Yang; Yongjian Zhou
Journal:  Oncol Lett       Date:  2018-03-06       Impact factor: 2.967

Review 2.  The role of microRNA in the resistance to treatment of hepatocellular carcinoma.

Authors:  Muhammad Yogi Pratama; Devis Pascut; Muhammad Nasrum Massi; Claudio Tiribelli
Journal:  Ann Transl Med       Date:  2019-10

Review 3.  MicroRNAs predict and modulate responses to chemotherapy in colorectal cancer.

Authors:  Xin Yu; Zheng Li; Jun Yu; Matthew T V Chan; William K K Wu
Journal:  Cell Prolif       Date:  2015-07-22       Impact factor: 6.831

Review 4.  microRNAs as pharmacogenomic biomarkers for drug efficacy and drug safety assessment.

Authors:  Igor Koturbash; William H Tolleson; Lei Guo; Dianke Yu; Si Chen; Huixiao Hong; William Mattes; Baitang Ning
Journal:  Biomark Med       Date:  2015-10-26       Impact factor: 2.851

5.  Epigenetic modulation of a miR-296-5p:HMGA1 axis regulates Sox2 expression and glioblastoma stem cells.

Authors:  H Lopez-Bertoni; B Lal; N Michelson; H Guerrero-Cázares; A Quiñones-Hinojosa; Y Li; J Laterra
Journal:  Oncogene       Date:  2016-02-22       Impact factor: 9.867

6.  Circulating DNA and Micro-RNA in Patients with Pancreatic Cancer.

Authors:  Eveline E Vietsch; Casper Hj van Eijck; Anton Wellstein
Journal:  Pancreat Disord Ther       Date:  2015-06

Review 7.  miRNAs: micro-managers of anticancer combination therapies.

Authors:  Judy R van Beijnum; Elisa Giovannetti; Dennis Poel; Patrycja Nowak-Sliwinska; Arjan W Griffioen
Journal:  Angiogenesis       Date:  2017-05-04       Impact factor: 9.596

Review 8.  Biomarkers of Angiogenesis in Colorectal Cancer.

Authors:  Luay Mousa; Mohamed E Salem; Sameh Mikhail
Journal:  Biomark Cancer       Date:  2015-10-27

9.  Circulating microRNA profile predicts disease progression in patients receiving second-line treatment of lapatinib and capecitabine for metastatic pancreatic cancer.

Authors:  Xuefei Tian; Narayan Shivapurkar; Zheng Wu; Jimmy J Hwang; Michael J Pishvaian; Louis M Weiner; Lisa Ley; Dan Zhou; Xiuling Zhi; Anton Wellstein; John L Marshall; Aiwu Ruth He
Journal:  Oncol Lett       Date:  2016-01-13       Impact factor: 2.967

10.  Double-strand break repair and colorectal cancer: gene variants within 3' UTRs and microRNAs binding as modulators of cancer risk and clinical outcome.

Authors:  Alessio Naccarati; Fabio Rosa; Veronika Vymetalkova; Elisa Barone; Katerina Jiraskova; Cornelia Di Gaetano; Jan Novotny; Miroslav Levy; Ludmila Vodickova; Federica Gemignani; Tomas Buchler; Stefano Landi; Pavel Vodicka; Barbara Pardini
Journal:  Oncotarget       Date:  2016-04-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.